Apricus Biosciences Inc. (NASDAQ:APRI): Alex Denner’s Sarissa Capital Management filed an amended 13D.
You can check out Sarissa Capital Management’s latest holdings and filings here.
Please follow Sarissa Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Sarissa Capital Management or update its stock holdings.
Follow Alex Denner's Sarissa Capital Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Sarissa Capital Management | 8 | 2,120,361 | 10 | 2,120,361 | 2,120,361 | 13.5 % |
| Alexander J. Denner | 8 | 2,120,361 | 10 | 2,120,361 | 2,120,361 | 13.5 % |
| Sarissa Capital Offshore Master Fund | 2,120,361 | 9 | 2,120,361 | 11 | 2,120,361 | 13.5 % |
Follow Alex Denner's Sarissa Capital Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 7 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
| Apricus Biosciences, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 652903-10-5 |
| (CUSIP Number) |
| Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 With a copy to: Russell Leaf Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, New York 10019 212-728-8000 |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
| January 31, 2018 |
| (Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 7
